Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a new contract by an existing client Cancer Research UK. The project involves the development of Pharmacokinetic Pharmacodynamic (PK/PD)* model to simulate the exposure-response relationship for a novel oncology therapy to guide starting dose and dose range for an upcoming First in Human Study.

Dr Peter Sargent, CEO, commented: "We are delighted to have been awarded this new contract with one of our existing clients. This contract reflects the impact of the services we provide and our continued relationship with Cancer Research UK".

* PKPD modelling is a scientific approach used to describe and predict the relationship between drug concentration in the body (PK) and the corresponding biological or physiological effect (PD). This supports the prediction of what the optimum drug dose needs to be to enable a therapeutic effect whilst minimising levels of toxicity.